Copyright: ©Author(s) 2026.
World J Hepatol. May 27, 2026; 18(5): 116995
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.116995
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.116995
Table 1 Baseline demographic, clinical, laboratory features, fibrosis stage, and IFI16 (rs1057028) and AIM2 (rs2814770) genotypic and allelic frequency in the present study population
| Characteristics | CHC patients (n = 378) |
| Age (years) | 40 (32-50) |
| BMI (kg/m2) | 26.8 (24-30) |
| HCV-RNA log10 (IU/mL) | 4.58 (3.75-5.41) |
| ALT (IU/L) | 59 (41-88) |
| AST (IU/L) | 55 (39.2-89.5) |
| Bilirubin (mg/dL) | 0.8 (0.7-0.9) |
| Metavir staging | |
| F0-F1 | 223 (59.5) |
| F2 | 17 (4.5) |
| F3 | 59 (15.7) |
| F4 | 76 (20.3) |
| IFI16 rs1057028 (n = 378) | |
| AA | 209 (55.3) |
| AT | 100 (26.5) |
| TT | 69 (18.3) |
| A | 518 (69) |
| T | 238 (31) |
| AIM2 rs2814770 (n = 140) | |
| CC | 41 (29.3) |
| CT | 60 (42.9) |
| TT | 39 (27.9) |
| C | 142 (51) |
| T | 138 (49) |
- Citation: Arshad I, Majid M, Rauff B, Amar A, Choudhery MS. Genetic polymorphism of IFI16 and AIM2 among Pakistani hepatitis C virus-induced fibrosis patients. World J Hepatol 2026; 18(5): 116995
- URL: https://www.wjgnet.com/1948-5182/full/v18/i5/116995.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i5.116995